August Newsletter

Golden Helix Named on Inc 5000 List of Fastest-Growing Private Companies for 3rd Consecutive Year 

Golden Helix Named on Inc 5000 List of Fastest-Growing Private Companies for 3rd Consecutive Year

By Andreas Scherer
President & CEO

This award is a testament to the dedication, ingenuity, and work ethics of the entire Golden Helix team. After numerous successful product launches in the clinical variant analysis space over the last three years, matched by an excellent execution of our go-to-market strategy, we are experiencing sustained growth in all key global markets. I would like to thank my entire team for this outstanding achievement. Also, I would like to thank our customers and partners for their loyalty and commitment to us as a company... Read More

Manage gene lists across projects with VarSeq and VSClinical

Manage gene lists across projects with VarSeq and VSClinical

By Nate Fortier, PhD
Director of Research

Clinical labs often maintain gene panels, which are lists of genes with evidence of disease association. These panels are used to prioritize variants and limit interpretations to a predefined set of test-specific genes. In general, gene panels should be stored independently of any specific project or interpretation, as it is common for an individual gene panel to be generally applicable…Read More

PhoRank 2.0 Webcast Highlights

How a neonate’s rash can be one of your most important pieces of data

By Tisza Bell, PhD
Field Application Scientist 

The Genome Aggregation Database (gnomAD) is a resource developed by an international coalition of investigators, with the goal of aggregating and harmonizing both exome and genome sequencing data from a wide variety of large-scale sequencing projects (1). We have covered this annotation in-depth in other blog posts, but this resource contains over 125,000 exome sequences and around 16,000 whole genome… Read More



CEO Corner
New eBook: Clinical Variant Analysis for Cancer

We are extremely honored to share that our company was named to the 2021 Inc 5000 list. This is our third consecutive year of receiving this award which is an incredible achievement for the Golden Helix Team. I am very proud and appreciative of everyone working here. Equally, I would like to thank our customers and partners for their continuous support and commitment. As most of us know, our world is experiencing significant increases in daily expenses. Our company has been able to absorb the increases in our internal and external costs by gaining more market share across the globe. We are extremely grateful for our customers and would like to extend this gratitude by committing to not raising prices this year. We hope this enables current and future customers to grow their NGS offerings without the added stress of price fluctuations. Thank you again for the great support, we could not do this without our community.

Recent Talks

We enjoyed presenting two Corporate Satellite talks at the ESHG 2021 Virtual Conference! If you did not have a chance to make the live sessions, you can access the on-demand sessions in the ESHG portal.

VSClinical: a comprehensive NGS clinical solution
Presented by Andreas Scherer, PhD, Darby Kammeraad, Julia Love, Eli Sward, PhD

Watch the Recording

Supporting the new ACMG guidelines for NGS-based CNVs for genetic testing labs

Presented by Andreas Scherer, Gabe Rudy, Nate Fortier, PhD

Watch the Recording
Customer Success

Congratulations to all of our customers who have published this month! To highlight just a few:

Identification of Maturity-Onset-Diabetes of the Young (MODY) mutations in a country where diabetes is endemic - Fahd Al-Mulla & Colleagues, Dasman Center for Research and Treatment of Diabetes / Published in Nature

Familial Hypercholesterolemia, Familial Combined Hyperlipidemia and Elevated Lipoprotein(a) in Patients with Premature Coronary Artery Disease - Mark Trinder & Colleagues, University of British Columbia / Published in Canadian Journal of Cardiology

About Golden Helix

Golden Helix has been delivering industry-leading bioinformatics solutions for the advancement of life science research and translational medicine for over 20 years with 1,000s of users around the world. Their innovative technologies and analytic services empower scientists and healthcare professionals at all levels to derive meaning from the rapidly increasing volumes of genomic data produced from NGS sequencers and microarrays. With their solutions, hundreds of the world's top hospitals, testing labs, pharmaceutical, biotech, and academic research organizations can harness the full potential of genomics to identify the cause of disease, improve the efficacy and safety of drugs, develop genomic diagnostics, and advance the quest for personalized medicine.